BioLineRx, Ltd. (NASDAQ:BLRX) moved up 5.26% and closed its last trading session at $1.2. This Medical Sector stock currently has the Market Capitalization of 67.72 Million. The Average Volume for the stock is measured as 394.6 Million. The Stock has a 52-Week High of $1.42 and 52-Week Low of $0.71 following the dates, it touched its 52-Week High on Sep 23, 2016 and 52-Week Low on Jun 27, 2016. Currently, the Return on Assets value for the trailing twelve months is 0% with the Return on Equity and Return on Investment of 0% and 0% respectively. This firm currently has YTD (year to date) performance of 30.43 Percent which is awesome. The Short Ratio for the stock is 0.53.
BioLineRx, Ltd. (NASDAQ:BLRX) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-0.27. The TTM operating margin is 0 percent.
BioLineRx, Ltd. (NASDAQ:BLRX) reports its Earnings on Thu 9 Mar (10 days ago). The estimated EPS for the current quarter is said to be $-0.08. Following Earnings result, share price were DOWN 4 times out of last 8 Qtrs. The stock has added about 13.2% since it reported its last earnings. The Closing price of BioLineRx, Ltd. (NASDAQ:BLRX) at Last Earnings was $ as compared to the previous closing price of $1.2. The Predicted Move on the 7th day after BioLineRx, Ltd. (NASDAQ:BLRX) will release its earnings at about 5%.
By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, BioLineRx, Ltd. (NASDAQ:BLRX) beats earnings by 33%, The Stock Missed Earnings 5 times and has met earnings 2 times.
We will discuss the past Quarters Earnings below:
On 11/22/2016, Analysts were suspecting EPS of $-0.08/share where BioLineRx, Ltd. (NASDAQ:BLRX) reported its Actual EPS of $-0.06. Thus showing a Surprise of 25 percent. The Closing Price of the stock before earnings was $1.06 while on the Next day the stock closed its trading session at $1.1 with a percentage change of 3.77% from the price of 1.06 before Earnings. The Stock Closing Price on the 7th day of earnings was $1.05.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of three primary clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; BL-7010, a novel co-polymer for the treatment of celiac disease and gluten sensitivity; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companys other therapeutic candidates comprise BL-8020, an orally available treatment for the hepatitis C virus, and other viral indications; and BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction. It also has a preclinical stage therapeutic candidate, BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas. The company has strategic collaborations with Novartis Pharma AG; Merck; The University of Texas MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech, Inc. to support various Phase Ib studies investigating the companys BL-8040 in combination with the Genentechs Atezolizumab in multiple cancer indications. BioLineRx Ltd. was founded in 2003 and is headquartered in Modiin, Israel.